Pfizer Venture Investments
VC Fund
New York, United States
Pfizer Venture Investments is a corporate venture capital firm that invests in areas of current or future strategic interest to Pfizer. It aims to remain at the forefront of life science advances. It identifies and invests in emerging companies that are developing transformative medicines and technologies that have the potential to enhance Pfizer’spipeline and shape the future of its industry.
- Total investments:
- 182
- Last investment:
- Lead investor:
- 27%
- Fund size:
- $600M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Pfizer Venture Investments invests in
Stages Pfizer Venture Investments invests in
Countries Pfizer Venture Investments invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
1 more contact available
Round size
- Series A
- $10M–$100M
- Series B
- $20M–$120M
- Series C
- $15M–$102M
Investment Focus
Industry
- Biotechnology 101 (55%)
- Health Care 68 (37%)
- Therapeutics 51 (28%)
- Medical 29 (16%)
- Pharmaceutical 28 (15%)
Stage
- Series B 53 (29%)
- Series A 44 (24%)
- Series C 24 (13%)
- Funding Round 17 (9%)
- Seed 7 (4%)
Country
- United States 84 (46%)
- United Kingdom 11 (6%)
- Switzerland 6 (3%)
- China 3 (2%)
- France 2 (1%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Albert Bourla
Chairman & CEO
|
Chairman & CEO | Total investments: 0 | Find email | |
Dan Littman
Managing Director
|
Managing Director | Total investments: 0 | Find email | |
Helen Hobbs
Managing Director
|
Managing Director | Total investments: 0 | Find email | |
Margi McLoughlin
Partner
|
Partner | Total investments: 2 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Flare Therapeutics
|
Flare Therapeutics is a biotechnology company opening up a new therapeutic space with a novel approach to decipher the biology of transcription factors to develop small molecule medicines. Based on insights from the seminal work of its scientific founders, Flare’s team has uncovered ‘switch sites,’ druggable regions that are key targets fortranscription factor regulation to address mutations that cause disease. Its drug discovery to target switch sites has rapidly advanced, resulting in an emerging pipeline of drug programs that address well-validated transcription factors, initially focused on precision oncology with future potential in neurology, rare genetic disorders, immunology, and inflammation. | $85M / Series C / Jun 30, 2026 | |
Engine Biosciences
|
Engine Biosciences is a biotech company that applies machine learning to genomics for drug discovery.Engine Biosciences is a venture-backed San Francisco- and Asia-based technology company pioneering network biomedicine. The company's proprietary and patented technologies oriented around deciphering the complexity of biology networks includeboth high-throughput wet lab experimentation and artificial intelligence algorithms for drug discovery and cellular reprogramming. This platform, developed through several years of research by our scientific founding and leadership team who include faculty members at MIT, Harvard, Mayo Clinic, and UCSD, dramatically accelerates and reduces costs of the R&D process for new medical therapies. We are actively applying the platform internally and with partners across a range of disease indications. | Venture - Series Unknown / Jun 29, 2026 | |
Oblenio Bio
|
Oblenio Bio is a biotechnology company that develops T-cell engager therapeutic candidates for autoimmune disease treatment. | $62M / Series B / Jun 25, 2026 | |
TRIMTECH Therapeutics
|
TRIMTECH Therapeutics is a biotech organization that treats neurodegenerative illnesses by using targeted protein degradation (TPD). | $14M / Seed / Jun 23, 2026 | |
Cour Pharmaceuticals Development
|
Cour Pharmaceuticals Development Co Inc operates in the pharmaceutical sector. Cour Pharmaceuticals Development Co Inc was founded in 2012 and is based in Elmhurst, Illinois. | $50M / Series B / Jun 18, 2026 | |
Storm Therapeutics
|
Targeting pathways that modify RNA to deliver novel cancer therapeutics. | $56M / Series C / Apr 16, 2026 | |
Crossbow Therapeutics
|
Crossbow Therapeutics is a seed-stage, stealth-mode oncology startup company. The company develops antibody engineering for intracellular cancer targets. | $77M / Series B / Mar 18, 2026 | |
TRex Bio
|
TRexBio is a discovery stage biotechnology company leveraging cutting-edge computational biology tools, a focus on human tissue, and expertise in immunobiology to develop revolutionary therapeutics for cancer and inflammatory diseases. Our powerful ‘deep biology’ discovery engine maps human tissue Treg behavior to disease processes, allowing us toidentify and characterize novel targets for therapeutic intervention. Leveraging this platform, we are building a broad portfolio of novel therapies that modulate the immune system to restore human tissue immune homeostasis. | $50M / Jan 27, 2026 | |
Vibrant
|
Vibrant develops an AI drug development platform to focus on building immune system-related drug pipelines. The company will use artificial intelligence algorithms to accelerate the efficiency of drug development in various aspects such as target discovery, drug design, and drug efficacy evaluation; at the same time, the company expects tocontinuously improve the success rate of drug development through sustainable data accumulation and algorithm optimization.It was founded and headed by Dr. Wang Luquan and is based in Guangzhou, Guangdong, China. | $61M / Jan 12, 2026 | |
Enodia Therapeutics
|
Enodia Therapeutics is a biotech company that provides transforming treatments for cancer, inflammation, and viral infection diseases. | $24.2M / Seed / Jan 08, 2026 | |
| See all 182 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does Pfizer Venture Investments invest in?
Pfizer Venture Investments invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series B and Series A stage. Most of the 182 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Pfizer Venture Investments's check size?
Pfizer Venture Investments typically joins rounds of $10M–$100M at Series A, $20M–$120M at Series B and $15M–$102M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Pfizer Venture Investments participates in.
How do I contact Pfizer Venture Investments?
Public channels for Pfizer Venture Investments include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Pfizer Venture Investments?
The team at Pfizer Venture Investments includes Albert Bourla (Chairman & CEO), Dan Littman (Managing Director) and Helen Hobbs (Managing Director). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
